Summary
Definition
History and exam
Key diagnostic factors
- presence of risk factors
- age >19 years
- unilateral scrotal pain and swelling of gradual onset
- symptoms <6 weeks' duration
- tenderness
- hot, erythematous, swollen hemiscrotum
- frequent and painful micturition
- purulent urethral discharge
Other diagnostic factors
- pyrexia
- fluctuant swelling or induration of scrotal tissue
- enlarged or tender prostate
Risk factors
- unprotected sexual intercourse
- bladder outflow obstruction
- instrumentation of urinary tract
- immunosuppression
- vasculitis
- amiodarone
- mumps
- exposure to tuberculosis (TB)
Diagnostic investigations
1st investigations to order
- Gram stain of urethral secretions
- urine dipstick test
- urine microscopy
- urine culture
- nucleic acid amplification test (NAAT) of urethral secretions or first-void urine for Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium
- culture of urethral secretions
Investigations to consider
- scrotal colour duplex ultrasonography
- surgical exploration
- 3 early morning urine samples for acid-fast bacilli staining, culture, and NAAT for Mycobacterium tuberculosis
- HIV test
- syphilis test
Treatment algorithm
Contributors
Authors
Ameeta E. Singh, BMBS(UK), MSc, FRCPC, FIDSA
Clinical Professor
Division of Infectious Diseases
University of Alberta
Edmonton
Canada
Disclosures
AES declares that she has no competing interests.
Acknowledgements
Dr Ameeta E. Singh would like to gratefully acknowledge Dr Hossein Sadeghi-Nejad, Dr Lorenzo DiGiorgio, Dr Mary Garthwaite, and Dr Ian Eardley, previous contributors to this topic.
Disclosures
HSN, LDG, and MG declare that they have no competing interests. IE is a consultant to Pfizer, Lilly, and Sanofi. He is a speaker for Lilly.
Peer reviewers
Sheldon Morris, MD, MPH
Assistant Professor
Division of Infectious Diseases
Department of Medicine
UCSD Antiviral Research Center
Division of Family Medicine
Department of Family and Preventive Medicine
UCSD La Jolla Family and Sports Medicine
San Diego
CA
Disclosures
SM has received research funding support from NIH CHRP, CIRM, and Gilead Sciences. He has financial interests in Impact Biomedicines (now Celgene) and Forty Seven Inc. There is no conflict between these financial interests and any content in this topic.
Altaf Mangera, MBChB (Hons), MD, FRCS (Urol), FEBU
Consultant Urologist
Department of Urology
Royal Hallamshire Hospital
Sheffield
UK
Disclosures
AM declares that he has no competing interests.
Use of this content is subject to our disclaimer